Smith MR, Jegede O, Martin P, Till B, et al. Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma. Blood 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962.
PMID: 38820500